Operational research as a mechanism to improve treatment outcomes for drug-resistant TB in the WHO European Region

Operational research as a mechanism to improve treatment outcomes for drug-resistant TB in the WHO European Region

In 2022, the WHO European Region accounted for 15.1% of all incident rifampicin-resistant/multidrug-resistant TB (RR/MDR-TB) cases. Most occurred in 18 high-priority countries of eastern Europe and central Asia, many of which joined an initiative led by the WHO Regional Office for Europe. The aim wa...

Full description

Saved in:
Bibliographic Details
Main Authors: G.B. Migliori, O. Korotych, J. Achar, A. Ciobanu, G. Dravniece, M. Germanovych, E. Gurbanova, A. Hovhannesyan, N. Khachatryan, L. Kuksa, N. Lomtadze, M.L. Rich, A. Skrahina, A. Yedilbayev
Format: Article
Language:English
Published: International Union Against Tuberculosis and Lung Disease (The Union) 2024-03-01
Series:IJTLD Open
Subjects:
tuberculosis
mdr-tb
shorter regimens
rifampicin resistant
mstr
Online Access:https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2024/00000001/00000003/art00002
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2024/00000001/00000003/art00002

Similar Items